Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 487

The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.

Antibody 10-1074 suppresses viremia in HIV-1-infected individuals

Open access
Caskey, Marina, Schoofs, Till, Gruell, Henning, Settler, Allison, Karagounis, Theodora, Kreider, Edward F, Murrell, Ben, Pfeifer, Nico, Nogueira, Lilian, Oliveira, Thiago Y, Learn, Gerald H, Cohen, Yehuda Z, Lehmann, Clara, Gillor, Daniel, Shimeliovich, Irina, Unson-O'Brien, Cecilia, Weiland, Daniela, Robles, Alexander, Kümmerle, Tim, Wyen, Christoph, Levin, Rebeka, Witmer-Pack, Maggi, Eren, Kemal, Ignacio, Caroline, Kiss, Szilard, West, Anthony P, Mouquet, Hugo, Zingman, Barry S, Gulick, Roy M, Keler, Tibor, Bjorkman, Pamela J, Seaman, Michael S, Hahn, Beatrice H, Fätkenheuer, Gerd, Schlesinger, Sarah J, Nussenzweig, Michel C, Klein, Florian·2017·Nature Medicine

Abstract

Monoclonal antibody 10-1074 targets the V3 glycan supersite on the HIV-1 envelope (Env) protein. It is among the most potent anti-HIV-1 neutralizing antibodies isolated so far. Here we report on its safety and activity in 33 individuals who received a single intravenous infusion of the antibody. 10-1074 was well tolerated and had a half-life of 24.0 d in participants without HIV-1 infection and 12.8 d in individuals with HIV-1 infection. Thirteen individuals with viremia received the highest dose of 30 mg/kg 10-1074. Eleven of these participants were 10-1074-sensitive and showed a rapid decline in viremia by a mean of 1.52 log10 copies/ml. Virologic analysis revealed the emergence of multiple independent 10-1074-resistant viruses in the first weeks after infusion. Emerging escape variants were generally resistant to the related V3-specific antibody PGT121, but remained sensitive to antibodies targeting nonoverlapping epitopes, such as the anti-CD4-binding-site antibodies 3BNC117 and VRC01. The results demonstrate the safety and activity of 10-1074 in humans and support the idea that antibodies targeting the V3 glycan supersite might be useful for the treatment and prevention of HIV-1 infection.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nm.4268

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 65 references

Cited by

Metadata

Authors
Caskey, M., Schoofs, T., Gruell, H., Settler, A., Karagounis, T., Kreider, E. F., Murrell, B., Pfeifer, N., Nogueira, L., Oliveira, T. Y., Learn, G. H., Cohen, Y. Z., Lehmann, C., Gillor, D., Shimeliovich, I., Unson-O'Brien, C., Weiland, D., Robles, A., Kümmerle, T., Wyen, C., Levin, R., Witmer-Pack, M., Eren, K., Ignacio, C., Kiss, S., West, A. P., Mouquet, H., Zingman, B. S., Gulick, R. M., Keler, T., Bjorkman, P. J., Seaman, M. S., Hahn, B. H., Fätkenheuer, G., Schlesinger, S. J., Nussenzweig, M. C., & Klein, F.
Venue
Nature Medicine
Published
2017-01-16
Volume
23
Issue
2
Pages
185-191
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W2572760626
Cited by
487
References
65
FWCI
30.47
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.